HVE Stock Overview
Engages in the development and commercialization of pharmaceutical products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Innoviva, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$16.70 |
| 52 Week High | US$19.10 |
| 52 Week Low | US$13.90 |
| Beta | 0.36 |
| 1 Month Change | 3.73% |
| 3 Month Change | -3.47% |
| 1 Year Change | 15.17% |
| 3 Year Change | 18.44% |
| 5 Year Change | 31.50% |
| Change since IPO | 68.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| HVE | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.6% | 2.0% | -0.9% |
| 1Y | 15.2% | -25.8% | 14.1% |
Return vs Industry: HVE exceeded the German Pharmaceuticals industry which returned -25.8% over the past year.
Return vs Market: HVE exceeded the German Market which returned 14.1% over the past year.
Price Volatility
| HVE volatility | |
|---|---|
| HVE Average Weekly Movement | 3.2% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: HVE has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: HVE's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 127 | Pavel Raifeld | www.inva.com |
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline), a tetracycline class antibacterial for the treatment of complicated intra-abdominal infections in adults; XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; and ZEVTERA, a cephalosporin antibacterial for the treatment of adult patients with staphylococcus aureus bloodstream infections, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients with community-acquired bacterial pneumonia. Its development pipeline includes Zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea.
Innoviva, Inc. Fundamentals Summary
| HVE fundamental statistics | |
|---|---|
| Market cap | €1.05b |
| Earnings (TTM) | -€52.58m |
| Revenue (TTM) | €325.57m |
Is HVE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HVE income statement (TTM) | |
|---|---|
| Revenue | US$369.84m |
| Cost of Revenue | US$41.42m |
| Gross Profit | US$328.42m |
| Other Expenses | US$388.15m |
| Earnings | -US$59.72m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.95 |
| Gross Margin | 88.80% |
| Net Profit Margin | -16.15% |
| Debt/Equity Ratio | 79.9% |
How did HVE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/24 08:16 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innoviva, Inc. is covered by 17 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jon Langenfeld | Baird |
| James Birchenough | Barclays |
| Patrick Trucchio | Berenberg |